Part 2/8:
Gilead Sciences has positioned itself as a titan in the biotechnology sector, notably for its innovative hepatitis C treatments. The company’s portfolio includes two of the best-selling hepatitis C drugs, the combined sales of which exceed those of the established blockbuster Humira by AbbVie by billions annually. This put Gilead at the forefront of hepatitis C therapies, creating a narrative of success and dominance.